Cancer
Malignant Prostate Neoplasm
CI-CAN-00005927Explore in graph →
Top-level1,377 active trials24 approved drugs58 evidence items
- NCIt
- C7378
- ICD-10
- C61
- DOID
- 10283
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00005927Explore in graph →
Clinical trials
5,981 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (730)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02958787 | Vessel Sparing Prostate Radiation Therapy | completed | Phase 2 | 135 | University of Michigan Rogel Cancer CenterOTHER | 1 | Mar 5, 2018 | clinicaltrials |
| NCT01120236 | Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer | completed | Phase 2 | 211 | National Cancer Institute (NCI)NIH | 2 | Feb 26, 2018 | clinicaltrials |
| NCT00744549 | Study of Antioxidants on MRI Detectable Early Stage Prostate Cancer Among Men on Active Surveillance | completed | Phase 2 | 16 | University Health Network, TorontoOTHER | 1 | Feb 14, 2018 | clinicaltrials |
| NCT01289067 | Utilizing A Genomic Sig for "BRCAness" to Eval the Efficacy of Satraplatin in Men With Met. Castration Resistant Prostate Ca | completed | Phase 2 | 13 | William K. OhOTHER | 1 | Feb 13, 2018 | clinicaltrials |
| NCT00878436 | Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration | completed | Phase 1 / Phase 2 | 52 | NYU Langone HealthOTHER | 1 | Feb 7, 2018 | clinicaltrials |
| NCT02097303 | Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis(eRADicAte) | completed | Phase 2 | 36 | Carolina Research Professionals, LLCOTHER | 1 | Feb 1, 2018 | clinicaltrials |
| NCT00983710 | Prostate Cancer Symptom Management for Low Literacy Men | completed | Phase 2 | 108 | Baylor College of MedicineOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT01105338 | Lycopene or Green Tea for Men at Risk of Prostate Cancer(ProDiet) | completed | Phase 2 / Phase 3 | 126 | University of BristolOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT00814788 | Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer(UCDCC#215) | completed | Phase 2 | 24 | University of California, DavisOTHER | 1 | Jan 10, 2018 | clinicaltrials |
| NCT01433913 | Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Jan 10, 2018 | clinicaltrials |
| NCT01199146 | Abiraterone Post Ketoconazole for Prostate Cancer | completed | Phase 2 | 42 | University of California, San FranciscoOTHER | 1 | Jan 8, 2018 | clinicaltrials |
| NCT00630344 | RAD001 and Bicalutamide for Androgen Independent Prostate Cancer | completed | Phase 2 | 36 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 8, 2017 | clinicaltrials |
| NCT00307294 | Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC) | completed | Phase 2 | 40 | University of PittsburghOTHER | 1 | Nov 24, 2017 | clinicaltrials |
| NCT00466752 | Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer | completed | Phase 2 | 5 | University of WashingtonOTHER | 1 | Nov 22, 2017 | clinicaltrials |
| NCT00331344 | Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy | completed | Phase 1 / Phase 2 | 100 | National Cancer Institute (NCI)NIH | 1 | Oct 31, 2017 | clinicaltrials |
| NCT00844792 | Study of Antioxidants on Prostate Tumors in Men Undergoing Radical Prostatectomy for Prostate Cancer | completed | Phase 2 | 48 | University Health Network, TorontoOTHER | 1 | Oct 26, 2017 | clinicaltrials |
| NCT01992042 | Novel Window of Opportunity Trial to Evaluate the Impact of Statins to Oppose Prostate Cancer | completed | Phase 2 | 33 | University Health Network, TorontoOTHER | 1 | Oct 26, 2017 | clinicaltrials |
| NCT01288534 | Hypofractionated Stereotactic Body Radiation Therapy (SBRT) | completed | Phase 2 | 68 | University of Michigan Rogel Cancer CenterOTHER | 1 | Oct 24, 2017 | clinicaltrials |
| NCT01756638 | A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer | completed | Phase 2 | 48 | Janssen Research & Development, LLCINDUSTRY | 1 | Oct 23, 2017 | clinicaltrials |
| NCT00887458 | A Two-dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal Therapy | completed | Phase 2 | 46 | Johns Hopkins UniversityOTHER | 1 | Oct 16, 2017 | clinicaltrials |
| NCT00953225 | Vitamin D Supplementation in Veterans With Early-Stage Prostate Cancer(vit D & PCa) | completed | Phase 2 | 83 | VA Office of Research and DevelopmentFED | 1 | Oct 9, 2017 | clinicaltrials |
| NCT00589472 | Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer(TARGET) | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Oct 6, 2017 | clinicaltrials |
| NCT00195039 | Treatment With Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Metastatic Prostate Cancer | completed | Phase 2 | 47 | Weill Medical College of Cornell UniversityOTHER | 1 | Oct 5, 2017 | clinicaltrials |
| NCT03297385 | Dynamics of Androgen Receptor Genomics and Transcriptomics After Neoadjuvant Androgen Ablation(DARANA) | completed | Phase 2 | 50 | The Netherlands Cancer InstituteOTHER | 0 | Sep 29, 2017 | clinicaltrials |
| NCT01834651 | A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases | completed | Phase 2 | 17 | Edwin Posadas, MDOTHER | 1 | Sep 27, 2017 | clinicaltrials |
| NCT00078585 | PROSTVAC®-VF/TRICOM™ Vaccine for the Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy | completed | Phase 2 | 120 | Bavarian NordicINDUSTRY | 1 | Sep 11, 2017 | clinicaltrials |
| NCT00585962 | Proton Beam Radiation Therapy for Early Stage Adenocarcinoma of the Prostate | completed | Phase 2 | 57 | Massachusetts General HospitalOTHER | 1 | Sep 5, 2017 | clinicaltrials |
| NCT00678054 | Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for Patients With Rising Prostate-Specific Antigen (PSA) | completed | Phase 2 | 30 | University of California, San FranciscoOTHER | 1 | Aug 23, 2017 | clinicaltrials |
| NCT00251225 | A Study of Imatinib and Docetaxel in Prostate Cancer | completed | Phase 2 | 49 | Leonard ApplemanOTHER | 1 | Aug 9, 2017 | clinicaltrials |
| NCT00551525 | Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer | completed | Phase 2 | 67 | Radiation Therapy Oncology GroupNETWORK | 1 | Jul 25, 2017 | clinicaltrials |
| NCT00005096 | Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer | completed | Phase 2 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 14, 2017 | clinicaltrials |
| NCT00924313 | Positron Emission Tomography and Magnetic Resonance Imaging for Prostate Cancer | completed | Phase 1 / Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jul 11, 2017 | clinicaltrials |
| NCT01240629 | Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 43 | University of Southern CaliforniaOTHER | 1 | Jul 11, 2017 | clinicaltrials |
| NCT00005916 | PSA-Based Vaccine and Radiotherapy to Treat Localized Prostate Cancer | completed | Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00246753 | Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy(NRR) | completed | Phase 2 | 29 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 28, 2017 | clinicaltrials |
| NCT01023061 | Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer(RAD1) | completed | Phase 2 | 24 | University of WashingtonOTHER | 1 | Jun 6, 2017 | clinicaltrials |
| NCT00225420 | Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer(NRR) | completed | Phase 1 / Phase 2 | 23 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 1, 2017 | clinicaltrials |
| NCT01431391 | Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer | completed | Phase 2 | 68 | DendreonINDUSTRY | 1 | May 30, 2017 | clinicaltrials |
| NCT00658697 | Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer | completed | Phase 2 | 42 | Dana-Farber Cancer InstituteOTHER | 1 | May 25, 2017 | clinicaltrials |
| NCT00486642 | Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | May 24, 2017 | clinicaltrials |
| NCT02105675 | Phase II Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer | completed | Phase 2 | 60 | SOTIO a.s.INDUSTRY | 1 | May 24, 2017 | clinicaltrials |
| NCT02107391 | Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer | completed | Phase 2 | 63 | SOTIO a.s.INDUSTRY | 1 | May 24, 2017 | clinicaltrials |
| NCT02107404 | Phase II Study of DCVAC/PCa Added After Radical Primary Prostatectomy for Patients With Localized Prostate Cancer | completed | Phase 2 | 150 | SOTIO a.s.INDUSTRY | 1 | May 24, 2017 | clinicaltrials |
| NCT02137746 | Study to Allow for Second Treatment Cycle of DCVAC in Patients With Localized Prostate Cancer | completed | Phase 2 | 24 | SOTIO a.s.INDUSTRY | 1 | May 24, 2017 | clinicaltrials |
| NCT00715078 | To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen | completed | Phase 2 | 122 | DendreonINDUSTRY | 1 | May 23, 2017 | clinicaltrials |
| NCT00901342 | Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer | completed | Phase 2 | 104 | DendreonINDUSTRY | 1 | May 23, 2017 | clinicaltrials |
| NCT00170157 | Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer | completed | Phase 2 | 112 | Mayo ClinicOTHER | 1 | May 15, 2017 | clinicaltrials |
| NCT02022371 | Prostate Cancer Genomic Heterogeneity(PROGENY) | completed | Phase 1 / Phase 2 | 50 | University College London HospitalsOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT00182741 | Calcitriol, Mitoxantrone, and Prednisone in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | 19 | OHSU Knight Cancer InstituteOTHER | 1 | May 3, 2017 | clinicaltrials |
| NCT00003781 | Docetaxel in Treating Patients With Stage IV Prostate Cancer | completed | Phase 2 | 25 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Mar 5, 2018source: clinicaltrials